DPIIT’s publication of the draft rules and draft Code of Conduct has provided an opportunity for stakeholders to share their views on the future regulatory framework for patent agents. Patent agents at BananaIP Counsels have responded with detailed comments at general and specific levels, offering suggestions that aim to make the framework more practical and suitable for modern patent practice. Their submission seeks to contribute to a balanced ecosystem that enables the continued growth of innovation in India.
Read more about Comments and Suggestions on Patent Agent Code of Conduct and Patent Rules DraftCategory: Patents
Urgency in Patent Infringement Disputes: Supreme Court on Mediation Requirement
In the case of Novenco Building and Industry A/S vs Xero Energy Engineering Solutions Pvt. Ltd., the Supreme Court ruled that mandatory mediation under the Commercial Courts Act can be bypassed in intellectual property cases where continuing infringement creates immediate harm. The Court stated that urgency must be assessed from the perspective of ongoing injury, not simply on the basis of when the suit was filed.
Read more about Urgency in Patent Infringement Disputes: Supreme Court on Mediation RequirementMadras High Court Overturns Patent Refusal for Ab Initio’s Data Lineage Invention
Madras High Court patent judgment backs Ab Initio’s data lineage invention, affirming novelty and inventive step in software patents.
Read more about Madras High Court Overturns Patent Refusal for Ab Initio’s Data Lineage InventionFMC Corporation’s Plea to Block Natco’s Cyantraniliprole Insecticide Formulation Denied
Delhi High Court refused FMC’s interim plea on a Cyantraniliprole intermediate, citing credible invalidity under Sections 64(1)(a) and 64(1)(e) and a tenable Gillette defence. With expiry close, damages suffice rather than an injunction.
Read more about FMC Corporation’s Plea to Block Natco’s Cyantraniliprole Insecticide Formulation DeniedCourt Clarifies Rules on Confidentiality Clubs and Comparable Licenses in SEP Patent Disputes: Nokia v. Asustek & Ors (2025)
Delhi Hight Court clarifies SEP rules on Confidentiality Clubs and license redactions in Nokia v. Asustek, allowing in-house access without restrictions.
Read more about Court Clarifies Rules on Confidentiality Clubs and Comparable Licenses in SEP Patent Disputes: Nokia v. Asustek & Ors (2025)Court Allows EMD Millipore’s IR Spectroscopy Patent, Clarifies Scope of Sections 3(i) and 59
Delhi HC green-lights EMD Millipore’s IR spectroscopy patent and narrows the sweep of Section 3(i), while affirming compliant claim amendments under Section 59.
Read more about Court Allows EMD Millipore’s IR Spectroscopy Patent, Clarifies Scope of Sections 3(i) and 59Frimline v. K-SMATCO: Delhi HC Rules Firmly in Pharmaceutical Patent Infringement Case
In Frimline v. K-SMATCO, Delhi HC granted interim relief over patent IN 382949, citing strong prima facie infringement of Frimline’s pharmaceutical formulation.
Read more about Frimline v. K-SMATCO: Delhi HC Rules Firmly in Pharmaceutical Patent Infringement CasePatent Refusal Cannot Be a Single Line: Calcutta High Court Calls for Reasoned Orders
In the case of Stromag GmbH vs. Controller General of Patents, the Calcutta High Court ruled that patent refusal orders must contain detailed reasoning. A single-line dismissal, the court said, does not meet the legal standards of a quasi-judicial function and is unsustainable.
Read more about Patent Refusal Cannot Be a Single Line: Calcutta High Court Calls for Reasoned OrdersInfrared-Based Biomolecule Detection is Not excluded under Section 3(i) of the Patents Act: Delhi HC
In the case of EMD Millipore Corporation vs Assistant Controller of Patents and Designs, the Delhi High Court held that a non-invasive method for analysing biomolecules is not excluded from patentability under Section 3(i). The Court allowed the applicant to revert to earlier claims and upheld the right to amend claims in appeal.
Read more about Infrared-Based Biomolecule Detection is Not excluded under Section 3(i) of the Patents Act: Delhi HCSection 3(i) and Diagnostic Patents: Court Upholds Refusal of Prenatal Testing Method
Delhi HC rules Sequenom’s NIPT methods are excluded as “diagnostic” under Section 3(i) and hit by 3(b) for sex selection concerns, while keeping the door open for tools and products.
Read more about Section 3(i) and Diagnostic Patents: Court Upholds Refusal of Prenatal Testing Method